+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027

  • ID: 4661511
  • Report
  • October 2018
  • Region: Global
  • 120 pages
  • DelveInsight
1 of 2
‘Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NMOSD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Disease Understanding and Treatment Algorithm

The Neuromyelitis Optica Spectrum Disorder market report gives the thorough understanding of the Neuromyelitis Optica Spectrum Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuromyelitis Optica Spectrum Disorder in the US, Europe, and Japan.

Neuromyelitis Optica Spectrum Disorder Epidemiology

The Neuromyelitis Optica Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female] and NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

According to this research, the prevalent cases of NMOSD was 32,382 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of NMOSD with 16,000 prevalent cases in 2016.

Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female], NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

Report Scope
  • The report covers detailed overview of Neuromyelitis Optica Spectrum Disorder explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Neuromyelitis Optica Spectrum Disorder
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM
Neuromyelitis Optica Spectrum Disorder Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Neuromyelitis Optica Spectrum Disorder Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Neuromyelitis Optica Spectrum Disorder Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Neuromyelitis Optica Spectrum Disorder market
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder market.
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Neuromyelitis Optica Spectrum Disorder: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2017
2.2. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2027

3. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview
3.1. Introduction
3.2. Signs and Symptoms
3.3. Clinical features of NMO/NMOSD
3.4. Classification
3.5. Pathogenesis
3.6. Diagnosis
3.7. International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders
3.8. Neuroimaging and neurophysiologic testing
3.8.1. Considerations for AQP4-IgG serologic and another laboratory testing.
3.8.2. Pediatric NMOSD criteria
3.8.3. Monophasic NMOSD
3.8.4. Systemic autoimmunity associated with NMOSD.
3.8.5. Pathology
3.8.6. Opticospinal MS

4. Epidemiology and Patient Population
4.1. Key Findings

5. 7MM Total Prevalent Patient Population of NMO/NMOSD

6. Country Wise-Epidemiology of NMO/NMOSD
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of NMO/NMOSD
6.1.3. Gender-Specific Prevalent Population of NMO/NMOSD
6.1.4. Total Diagnosed Population of NMO/NMOSD
6.1.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
6.1.6. Clinical Characterization of NMO/NMOSD
6.1.7. Events of NMO/NMOSD
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Total Prevalent Population of NMO/NMOSD
6.3.2. Gender-Specific Prevalent Population of NMO/NMOSD
6.3.3. Total Diagnosed Population of NMO/NMOSD
6.3.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
6.3.5. Clinical Characterization of NMO/NMOSD
6.3.6. Events of NMO/NMOSD
6.4. France
6.4.1. Total Prevalent Population of NMO/NMOSD
6.4.2. Gender-Specific Prevalent Population of NMO/NMOSD
6.4.3. Total Diagnosed Population of NMO/NMOSD
6.4.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
6.4.5. Clinical Characterization of NMO/NMOSD
6.4.6. Events of NMO/NMOSD
6.5. Italy
6.5.1. Total Prevalent Population of NMO/NMOSD
6.5.2. Gender-Specific Prevalent Population of NMO/NMOSD
6.5.3. Total Diagnosed Population of NMO/NMOSD
6.5.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
6.5.5. Clinical Characterization of NMO/NMOSD
6.5.6. Events of NMO/NMOSD
6.6. United Kingdom
6.6.1. Total Prevalent Population of NMO/NMOSD
6.6.2. Gender-Specific Prevalent Population of NMO/NMOSD
6.6.3. Total Diagnosed Population of NMO/NMOSD
6.6.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
6.6.5. Clinical Characterization of NMO/NMOSD
6.6.6. Events of NMO/NMOSD
6.7. Spain
6.7.1. Total Prevalent Population of NMO/NMOSD
6.7.2. Gender-Specific Prevalent Population of NMO/NMOSD
6.7.3. Total Diagnosed Population of NMO/NMOSD
6.7.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
6.7.5. Clinical Characterization of NMO/NMOSD
6.7.6. Events of NMO/NMOSD
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Prevalent Population of NMO/NMOSD
6.8.3. Gender-Specific Prevalent Population of NMO/NMOSD
6.8.4. Total Diagnosed Population of NMO/NMOSD
6.8.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
6.8.6. Clinical Characterization of NMO/NMOSD
6.8.7. Events of NMO/NMOSD

7. Market Drivers

8. Market Barriers

9. Appendix
9.1. Report Methodology

10. The Publisher's Capabilities

11. Disclaimer

12. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll